Oruka Therapeutics, Inc.
ORKA
Updated: 23/09/2026, 08:29:05
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
No summaries found.
- Share price
- $94.55
- Market cap
- $5.70B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Lawrence Otto Klein
- Employees
- 68
- IPO date
- 08/08/1997
- Beta
- -0.39
- Last dividend
- $0.00
- Day range
- $92.83 – $96.74
- 52-week range
- $14.89 – $115.52
- 1-day performance
- 1.25%
- 1-year performance
- 534.99%
- Current drawdown (1Y)
- -18.15%
- CIK
- 0000907654
- CUSIP
- 687604108
- ISIN
- US6876041087
- Created
- 07/12/2025, 05:37:36
- Last update
- 23/09/2026, 08:29:05
Track Oruka Therapeutics, Inc. with an AI analyst
See which prediction-market events move ORKA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research • STOCK • 12/06/2026, 15:01:14
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
Fool - Investing News • STOCK • 31/05/2026, 12:21:54
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
GlobeNewsWire • STOCK • 28/04/2026, 21:42:00
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Seeking Alpha • STOCK • 27/04/2026, 18:41:40
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
GlobeNewsWire • STOCK • 27/04/2026, 18:17:00
Orka (NASDAQ: ORKA) Stock Soars on Positive Trial Results and Analyst Upgrade
Market Data • Market Data • 27/04/2026, 18:10:33
Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001
Seeking Alpha • STOCK • 27/04/2026, 17:51:39
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
GlobeNewsWire • STOCK • 26/04/2026, 14:00:00
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?
Zacks Investment Research • STOCK • 17/03/2026, 11:55:27
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA
Defense World • STOCK • 14/03/2026, 04:07:16
Oruka Therapeutics: A Potential Future Psoriasis Play
Seeking Alpha • STOCK • 25/02/2026, 11:03:10
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
GlobeNewsWire • STOCK • 09/02/2026, 08:00:00